HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity

Salvarani, Carlo; Boiardi, Luigi; Mantovani, Vilma; Ranzi, Andrea; Cantini, Fabrizio; Olivieri, Ignazio; Bragliani, M; Collina, E.; Macchioni, P

doi:10.1136/ard.58.5.303

Cited by 45 publications

(22 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Acute phase reactants were examined by 16 studies (n=2067) 4 20 24 26 32 33 39 40 43 44 47 48 50 54 56 57. The parameter most commonly investigated was ESR, whereas C-reactive protein (six studies, n=722),4 24 32 33 39 57 interleukin 6 (one study, n=94)57 and plasma viscosity (one study, n=183)32 were less frequently tested.…”

Section: Resultsmentioning

confidence: 99%

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

et al. 2015

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

et al. 2015

View full text Add to dashboard Cite

“…Baseline factors that were associated with a higher relapse rate and/or prolonged therapy in PMR studies were: female sex (38,47), high erythrocyte sedimentation rate (ESR) (.40 mm/hour) (47)(48)(49)(50)(51)53) and peripheral inflammatory arthritis (54). A number of studies, however, failed to demonstrate association between these factors and relapse (48)(49)(50)(51)54,(67)(68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78). 4 Use the minimum effective dose out of a range of 12.5-25 mg prednisone equivalent daily: a high risk of relapse/prolonged therapy favors a higher dose, while a high risk of side effects favors a lower dose.…”

Section: Resultsmentioning

confidence: 99%

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative

Dejaco¹,

Singh

Perel

et al. 2015

Arthritis & Rheumatology

197

136

View full text Add to dashboard Cite

Therapy for polymyalgia rheumatica (PMR) varies widely in clinical practice as international recommendations for PMR treatment are not currently available. In this paper, we report the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of PMR. We used the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) methodology as a framework for the project. Accordingly, the direction and strength of the recommendations are based on the quality of evidence, the balance between desirable and undesirable effects, patients' and clinicians' values and preferences, and resource use. Eight overarching principles and nine specific recommendations were developed covering several aspects of PMR, including basic and follow-up investigations of patients under treatment, risk factor assessment, medical access for patients and specialist referral, treatment strategies such as initial glucocorticoid (GC) doses and subsequent tapering regimens, use of intramuscular GCs and disease modifying anti-rheumatic drugs (DMARDs), as well as the roles of non-steroidal anti-rheumatic drugs and non-pharmacological interventions. These recommendations will inform primary, secondary and tertiary care physicians about an international consensus on the management of PMR. These recommendations should serve to inform clinicians about best practices in the care of patients with PMR

show abstract

“…The association between HLA-DRB1 genotypes and susceptibility to polymyalgia rheumatica is controversial. Unlike PMR associated with GCA, which is generally associated with HLA-DRB1*04 alleles, the HLA-DRB1 susceptibility to isolated PMR varies in different populations (9,12). The association between HLA-DRB1*04 alleles and isolated PMR has been suggested by Salvarani et al, who reported a high incidence of HLA-DR1 among their Italian patients with isolated PMR (13).…”

Section: N Immunogeneticsmentioning

confidence: 96%

Pathogenesis of polymyalgia rheumatica

Guggino¹,

Ferrante²,

Macaluso³

et al. 2018

Reumatismo

View full text Add to dashboard Cite

REVIEW SUMMARYPolymyalgia rheumatica (PMR) is a chronic, inflammatory disorder of unknown cause, almost exclusively occurring in people aged over 50 and often associated with giant cell arteritis. The evidence that PMR occurs almost exclusively in individuals aged over 50 may indicate that age-related immune alterations in genetically predisposed subjects contribute to development of the disease. Several infectious agents have been investigated as possible triggers of PMR even though the results are inconclusive. Activation of the innate and adaptive immune systems has been proved in PMR patients as demonstrated by the activation of dendritic cells and monocytes/macrophages and the altered balance between Th17 and Treg cells. Disturbed B cell distribution and function have been also demonstrated in PMR patients suggesting a pathogenesis more complex than previously imagined. In this review we will discuss the recent findings regarding the pathogenesis of PMR.

show abstract

HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity

Cited by 45 publications

References 20 publications

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica

2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative

Pathogenesis of polymyalgia rheumatica

Contact Info

Product

Resources

About